Formulation and In-vivo Evaluation of Dasatinib-loaded Solid Lipid Nanoparticles
Abstract
The current research is aimed at formulation and in-vivo evaluation of dasatinib solid lipid nanoparticles (SLN) for enhanced solubility and bioavailability. A 33 Box-Behnken design (BBD) was used to optimize the formulations in which amount of glycerol monosterate(X1) the amount of poloxamer 407 (X2) and amount of tyloxopol (X3) were chosen as independent variables while particle size, entrapment efficiency and drug release after 12 hours were chosen as dependent variables. About 17 SLN formulations of dasatinib were prepared using glyceryl monostearate, poloxamer 407, Tyloxopol and Tween 80 and optimised using desirability function. All the SLNs were evaluated for fourier transform infrared spectroscopy (FTIR), particle size, zeta potential, entrapment efficiency and drug release behavior were investigated. The in-vivo pharmacokinetic evaluation of opimised SLN was carried out in rats. Based on BBD and desirability function the formulation comprising of X1:10, X2:06 and X3:02 was chosen optimal. The model was proven to be validated since a fine agreement existed between the predicted and observed results. It can be seen that the experimental values were in very close agreement with the predicted values, indicating the success of the BBD combined with a desirability function for the evaluation and optimization of SLNs formulations. The formulation DF10 displayed a mean particle size of 112 nm with PI of 0.40 and zeta potential of −25.6 mV.
The in-vitro release studies showed that more than 98.78% of drug was released from optimized SLN after 12 hours, which is higher when compared with marketed formulation. The release kinetics of the optimized formulation followed zero order drug release and best fitted the Korsemeyer-peppas model. At any time, point, the drug plasma concentrations in animals administrated with optimized SLN was higher than that of pure drug. Cmax of the dasatinib optimised SLN 158.26 ± 0.54 ng/mL was significant (p < 0.05) as compared to the pure drug suspension formulation 32.08 ± 0.21 ng/mL. Tmax of both optimised SLN formulation and pure drug was 1.0 ± 0.47 and 1.0 ± 0.04 hour, respectively AUC0-∞ infinity for dasatinib optimised SLN formulation was higher (702.23 ± 1.26 ng.h/mL) than the pure drug suspension 191.67 ± 1.27 ng.h/mL. Statistically, AUC0-t of the optimised SLN formulation was significantly higher (p < 0.05) as compared to pure drug suspension formulation. These results indicated that the dasatinib-loaded SLN formulation could potentially be exploited for the treatment of chronic myelogenous leukemia with controlled release manner.
Keywords:
Dasatinib, solid lipid nanoparticle, Box-Behnken design, in vivo and in vitro analysisDOI
https://doi.org/10.25004/IJPSDR.2022.140621References
Badawi A, El-Laithy H, El Qidra R, El Mofty H, El dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008;31(8):1040–1049.
De Jong W, Borm P. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–149.
Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2007;2(3):289–300.
Freitas C, Müller R. Correlation between long-term stability of solid lipid nanoparticles (SLN (TM)) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47(2):125–132.
Müller R, Rühl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14(4):458–462.
Mohamed Yasir A rafat h A , Jayk ar. Enhancement Of Ora l Bioavailability Via Solid Lipid Nanoparticles Of Anticancer Drug Dasatinib - An In-vitro Cytotoxicity And Pharmacokinetic Study. Asian J Pharm Clin Res. 2019; 6: 143-145.
Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. J Drug Target. 2013;21:515-27.
Mehnert W, Mader K. Solid lipid nanoparticles production, charac¬terization and applications. Adv Drug Deliv Rev. 2012;64:83-101.
Liu C, Wu C, Fang J. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug DevInd Pharm. 2010;36(7):751–761.
Arafath AA, MY. Enhancement of Oral Bioavailability via Solid Lipid Nanoparticles of Anticancer Drug Dasatinib - An In-vitro Cytotoxic¬ity and Pharmacokinetic Study. Asian J of Pharma and Clinical Res. 2019;12(6): 143-5.
ArchanaNerella, Basava Raju D, Aruna Devi M. Formulation, Optimi¬zation and In-vitro Characterization of Letrozole Loaded Solid Lipid Nanoparticles. Int. J of Pharm Sci and Drug Res. 2014; 6(3): 183-188.
Mehnert W, Mader K. Solid lipid nanoparticles: Production, charac¬terization and applications,Adv Drug Deliv Rev. 2001;47:165-174.
Huang Z, Hua S, Yang Y, Fang J. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacologica Sinica. 2008; 29(9):1094–1102
Chang J, Huang Y, Hou S, Wang R, Wu P, Tsai Y, Formulation optimization of meloxicam sodium gel using response surface methodology. Int J Pharm. 2007; 338(1–2):48–54.
Myers R, Montgomery D, Anderson-Cook C. Response surface methodology: process and product optimization using designed experiments. New York: John Wiley & Sons;2009; 73(1):25–33.
Rahman Z, Zidan A, Habib M, Khan M. Understanding the quality ofprotein loaded PLGA nanoparticles variability by Plackett- Burman design. Int J Pharm. 2010; 389(1–2):186–194.
Schwarz C, Mehnert W, Lucks J, Müller R. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Cont. Release. 1994;30(1):83–96.
Yang C, Zhao X, Hu H, et al. Preparation, Optimization and Characteristic of Huperzinea Loaded Nanostructured Lipid Carriers. Chem Pharm Bull. 2010; 58(5):656–661.
Kovacevic AB, Muller RH, Savic SD.. Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization and physical stability investigation. Colloid Surf A. 2014;444:15–25.
Chidambaram NW, Porter K. Flood, Qiu Y. Formulation and characterization of new layered diffusion matrices for zero-order sustained release. J Cont Release. 1998, 52: 149-158.
Bayomi MA. Geometric approach for zero-order release of drugs dispersed in an inert matrix. Pharm Res. 11; 1994: 914-916.
Zhang Z, Gao F, Bu H, Xiao J.Solid lipid nanoparticles loading dasatinib cilexetil enhance oral bioavailability: In-vitro characteristics and absorption mechanism in rats. Nanomedicine. 2012; 8:740–747.
Zhang Z, Gao F, Bu H, Xiao J. Solid lipid nanoparticles loading Dasatinib cilexetil enhances oral bioavailabilit y: In-v itro characteristics and absorption mechanism in rats. Nanomedicine 2012; 8:740–747
Narendar Dudhipala & Kishan Veerabrahma. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Del. 2016; 23: 395-404.
Levêque, D, Becker G, Bilger K . Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet. 2020; 59, 849–856.
Luo FR., Yang Z, Camuso A, Smykla R., McGlinchey K, Fager K. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Clinical Cancer Res. 2006;12(23):7180–7186.
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23:395-404. 12.
Published
Abstract Display: 464 
PDF Downloads: 421 
